



Tests you can trust

February 01, 2024

The National Stock Exchange of India Limited
Exchange Plaza
Bandera Kurla Complex,
Bandra (E), Mumbai - 400 051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001
(SCRIP CODE 539871)

Sub: Outcome of board meeting of Thyrocare Technologies Limited ("the Company") held on February 01, 2024

Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("SEBI Listing Regulations")

In continuation of our prior intimation dated January 24, 2024 regarding holding of a meeting of the Board of Directors of the Company ("Board"), we wish to inform you that the Board has, at its meeting held today i.e. February 01, 2024, *inter alia*, considered and approved the following matters:

1. the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2023.
2. appointment of Mr. Ankit Brijpuriya as Deputy Company Secretary and Deputy Compliance Officer of the Company w.e.f. February 01, 2024;

Pursuant to Regulation 33(3) of the SEBI Listing Regulations, copies of the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2023, along with the Limited Review Reports on said financial results issued by the Statutory Auditors of the Company are attached. The said financial results are also being made available on the Company's website at www.thyrocare.com and the extract is being published in one English and one Marathi newspaper.

Further, the details/disclosures required under Regulation 30 of the SEBI Listing Regulations, read the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed herewith as **Annexure -A**.

The meeting commenced at 3.45 pm and concluded at 4:45 pm today.

The highlights of the Company are as follows:

1. Partnerships (excluding API & B2G) revenue growth of 33% Y-o-Y
2. Franchise revenue growth of 11% Y-o-Y
3. Pathology (excluding materials & others) revenue grew by 8% Y-o-Y
4. Radiology revenue grew by 9% Y-o-Y
5. Execution of share purchase agreement for acquisition of 100% stake in Think Health Diagnostic Private Limited to foray into ECG at home services
6. Entered into partnership with TestEasy to introduce genome sequencing

This is for your information and records.

Yours Faithfully,
For **Thyrocare Technologies Limited**

Ramjee Dorai
Company Secretary and Compliance Officer

Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai- 400 703, India 📞 022- 3090 0000

✉️ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)

Annexure-A

Disclosure as per Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

Sl. No.	Particulars	Disclosures
1.	Reasons for change viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Ankit Brijpuriya (ACS37286) as Deputy Company Secretary and Deputy Compliance Officer of the Company
2.	Date of appointment and & term of appointment/re-appointment	Date of appointment: w.e.f. February 1, 2024 Terms of appointment: As per the employment agreement approved by the Nomination and Remuneration Committee and the Board of the Company
3.	Brief Profile (in case of appointment)	Mr. Ankit Brijpuriya a qualified Company Secretary and law graduate with a total of 10 years of post-qualification experience in legal and secretarial domains. He is currently working as Assistant General Manager in the Legal and Secretarial team of API Holdings Limited, Ultimate Holding Company of the Company. He is part of the key team to ensure compliance across API group and he has also been contributing towards ensuring compliances for various ongoing operations and projects at Thyrocare level.
4.	Disclosure of relationships between directors (in case of appointment of a director)	None

Independent Auditor's Review Report on unaudited Standalone financial results for the quarter and year to date of Thyrocare Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of Thyrocare Technologies Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Thyrocare Technologies Limited ('the Company') for the quarter ended December 31, 2023 and the year to-date results for the period from April 01, 2023 to December 31, 2023 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



MSKA & Associates

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W


Vaijayantimala Belsare
Partner
Membership No.: 049902
UDIN: 24049902BKCRDL7907

Place: Mumbai
Date: February 01,2024



Statement of Unaudited Standalone Financial Results for the Quarter and Nine Month Ended 31 December 2023

Particulars	Quarter ended			Nine month ended		Year ended
	31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	31 March 2023 (Audited)
1 Revenue from operations	122.89	136.29	117.17	382.79	361.64	486.46
2 Other Income	2.09	1.82	1.27	4.37	3.32	5.39
3 Total income	124.98	138.11	118.44	387.16	364.96	491.85
4 Expenses						
(a) Cost of materials consumed	35.99	40.70	37.26	111.79	112.97	150.06
(b) Purchase of stock-in-trade	0.68	0.38	1.35	1.41	4.29	6.11
(c) Charges in inventories of finished goods, work-in-progress and stock-in-trade	(0.27)	0.18	0.40	0.33	(0.53)	0.20
(d) Employee benefits expense	25.06	25.87	26.11	77.81	75.26	102.61
(e) Finance cost	0.96	1.02	0.59	2.78	1.65	2.25
(f) Depreciation and amortisation expense	10.90	9.30	9.01	28.71	24.66	34.08
(g) Other expenses	30.90	32.53	26.14	91.17	80.41	115.47
Total Expenses	104.22	109.98	100.86	314.00	298.71	410.78
5 Profit before exceptional items and tax (3 - 4)	20.76	28.13	17.58	73.16	66.25	81.07
6 Exceptional Items	-	-	-	-	-	-
7 Profit after exceptional items and before tax (5 - 6)	20.76	28.13	17.58	73.16	66.25	81.07
8 Tax expense						
(a) Current tax	(5.40)	(8.83)	(6.41)	(22.99)	(21.96)	(30.17)
(b) Deferred tax	(0.47)	0.99	1.46	1.74	2.75	6.07
9 Profit for the period/year (7 - 8)	14.89	20.29	12.63	51.91	47.04	56.97
10 Other comprehensive income (net of tax)						
(a) Items that will not be reclassified to profit or loss	0.01	0.07	-	0.30	0.42	2.06
(b) Income tax relating to items that will not be reclassified to profit or loss	(0.00)	(0.02)	-	(0.08)	(0.10)	(0.52)
11 Total comprehensive income for the period comprising of profit and other comprehensive income for the period / year (9 +10)	14.90	20.34	12.63	52.13	47.36	58.51
12 Paid-up equity share capital (Face Value of Rs. 10/-)	52.95	52.93	52.93	52.95	52.93	52.93
13 Other equity	-	-	-	-	-	468.11
14 Earnings Per Share (of Rs. 10/- each)*:						
(a) Basic	2.81	3.83	2.38	9.81	8.89	10.77
(b) Diluted	2.80	3.83	2.38	9.79	8.87	10.75

*not annualised except for the year ended 31 March

Notes:

- The above standalone unaudited financial results of the Company were reviewed and recommended by the Audit Committee on 1 February 2024 and subsequently approved by the Board of Directors at its meeting held on 1 February 2024. The review report has been filed with stock exchange and is available on the Company's website.
- The above unaudited standalone financial results for the quarter and nine month ended 31 December 2023 have been subjected to limited review by statutory auditors of the Company. The auditors have expressed an unmodified opinion in the limited review report for the quarter and nine month ended 31 December 2023.
- These unaudited standalone financial results have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.
- The Company has assessed the recoverable amount of the investment made in its wholly owned subsidiary Nuclear Healthcare Limited ('NHL') as value in use, being the higher of Fair Value less Cost of Disposal and Value in Use. For the current period, NHL has reported growth in its operations and has reported operating profit. For the quarter ended December 31, 2023, NHL has reported profit before tax of Rs. 0.06 Crores. Also, NHL still has accumulated losses carried forward from the previous years, hence the Company continues to assess the profitability and growth of NHL. The management does not foresee any further requirement of impairment of its investment made in NHL as at December 31, 2023 other than those already provided for in the books of account amounting to Rs. 44.33 Crores (31 March 2023 : INR 44.33 crore).
- During the quarter ended 31 December 2023, the company has granted 68,456 equity stock options to employees under the new scheme- Employees Stock Option Schemes 2023. During the quarter ended and nine month ended 31 December 2023, 4,097 equity stock options and 23,937 equity stock options granted to employees under employees stock option schemes but not vested on account of discontinuance of services of these employees, respectively, has been added back to the pool, which would be available for subsequent distribution subject to statutory rules and regulations, as applicable. The Company has also allotted 22,633 equity shares of Rs.10 each fully paid up on exercise of options by employees in accordance with Employee Stock Option scheme during the quarter ended 31 December 2023.
- In accordance with Ind AS 108 'Operating Segments', segment information has been given in the consolidated financial results of the Company.
- Previous periods/'years' figures have been regrouped/ reclassified wherever required, to make them comparable with the figure for the current period.

By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882



Rahul Guha
Managing Director
DIN - 09588432
Mumbai, 1 February 2024



Independent Auditor's Review Report on unaudited consolidated financial results for the quarter and year to date financial results of Thyrocare Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Thyrocare Technologies Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Thyrocare Technologies Limited ('the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') and its share of the net profit after tax of its associate for the quarter ended December 31, 2023 and the year to-date results for the period from April 01, 2023 to December 31, 2023 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Nueclear Healthcare Limited	Subsidiary
2	Pulse Hitech Health Services (Ghatkopar) LLP	Subsidiary
3	Equinox Labs Private Limited	Associate



MSKA & Associates

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the audit reports of another independent auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial information of one subsidiary included in the Statement, whose interim financial information reflects total revenues of Rs. 1.65 crore and Rs. 2.97 crore, total net (loss) after tax of Rs. (1.25) crore and Rs. (1.36) crore and total comprehensive (loss) of Rs. (1.25) crore and Rs. (1.36) crore, for the quarter ended December 31, 2023 and for the period from April 01, 2023 to December 31, 2023, respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 0.13 Crores and Rs. 0.60 Crores for the quarter ended December 31, 2023 and for the period from April 01, 2023 to December 31, 2023, respectively, as considered in the Statement, in respect of one associate, whose financial information has not been reviewed by us. This financial information has been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W


Vaijayantimala Belsare
Partner
Membership No.: 049902
UDIN: 24049902BKCRDM5652

Place: Mumbai
Date: February 01, 2024



THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: ramjee.d@thyrocare.com


Corporate Identity Number: L85110MH2000PLC123882

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine month Ended 31 December 2023

(Rs. in crore)

Particulars	Quarter ended		Nine month ended			Year ended
	31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	31 March 2023 (Audited)
1 Revenue from operations	134.74	148.00	128.03	417.63	390.79	526.67
2 Other Income	2.73	2.17	2.10	5.88	4.72	8.42
3 Total income	137.47	150.17	130.13	423.51	395.51	535.09
4 Expenses						
(a) Cost of materials consumed	38.01	43.08	39.11	118.39	117.72	156.92
(b) Purchase of stock-in-trade	0.68	0.38	1.35	1.41	4.29	6.11
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(0.27)	0.18	0.40	0.33	(0.53)	0.20
(d) Employee benefits expense	26.36	27.06	27.04	81.29	77.86	106.15
(e) Finance cost	1.07	1.13	0.58	3.08	1.68	2.35
(f) Depreciation and amortisation expense	13.47	10.65	10.15	33.95	27.91	38.71
(g) Other expenses	38.37	39.78	32.27	112.59	96.09	137.24
Total Expenses	117.69	122.26	110.90	351.04	325.02	447.68
5 Profit before exceptional items, share of profit/(loss) of associate and income tax (3 - 4)	19.78	27.91	19.23	72.47	70.49	87.41
6 Exceptional Items	-	-	-	-	-	-
7 Profit before share of profit/(loss) of associate and income tax	19.78	27.91	19.23	72.47	70.49	87.41
8 Share of profit/(loss) of associate	0.13	0.36	0.49	0.60	0.86	1.18
9 Profit before tax (7 - 8)	19.91	28.27	19.72	73.07	71.35	88.59
10 Tax expense						
(a) Current tax	(5.40)	(8.83)	(6.40)	(22.99)	(21.95)	(30.16)
(b) Deferred tax	0.23	0.89	1.38	2.23	2.47	5.93
11 Profit for the period (9 - 10)	14.74	20.33	14.70	52.31	51.87	64.36
12 Other Comprehensive income (net of tax)						
(a) Items that will not be reclassified to profit or loss	0.01	0.10	-	0.31	0.41	2.04
(b) Income tax relating to items that will not be reclassified to profit or loss	(0.01)	(0.02)	-	(0.08)	(0.10)	(0.51)
13 Total Comprehensive income for the period comprising Profit and other comprehensive income for the period / year (11 + 12)	14.74	20.41	14.70	52.54	52.18	65.89
14 Profit/(Loss) attributable to :						
(a) Owners of the company	15.35	20.34	14.72	52.98	51.89	64.49
(b) Non-controlling interest	(0.61)	(0.01)	(0.02)	(0.67)	(0.02)	(0.13)
	14.74	20.33	14.70	52.31	51.87	64.36
15 Total comprehensive income attributable to :						
(a) Owners of the company	15.35	20.42	14.72	53.21	52.20	66.02
(b) Non-controlling interest	(0.61)	(0.01)	(0.02)	(0.67)	(0.02)	(0.13)
	14.74	20.41	14.70	52.54	52.18	65.89
16 Paid-up equity share capital (Face Value of Rs. 10/-)	52.95	52.93	52.93	52.95	52.93	52.93
17 Other equity	-	-	-	-	-	481.37
18 Earnings Per Share (of Rs. 10/- each)*:						
(a) Basic	2.78	3.84	2.78	9.88	9.80	12.16
(b) Diluted	2.77	3.84	2.77	9.86	9.78	12.14
See accompanying note to the Financial Results						

*not annualised except for the year ended 31 March 2023



Notes:

1 Based on the "management approach" as defined in IndAS 108 - Operating Segments, the Chief Operating Decision Maker evaluates the Group's Performance. The Company has identified business segments as its primary segments. The Company recognizes its diagnostic testing services activity and imaging services including manufacturing of radiopharmaceuticals activity as its primary business segments. Diagnostic testing services operations predominantly consists of providing laboratory testing services to its customers. Imaging services segment represents PET-CT scan and sale of radio pharmaceuticals used in imaging services. Others represents trading and other related business activities. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments.

Particulars	(Rs. in crore)					Year ended 31 March 2023 (Audited)
	Quarter ended		Nine month ended			
	31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	
Segment Revenue						
Diagnostic Testing Services	122.43	136.75	115.74	381.12	358.01	481.22
Imaging Services	11.86	11.71	10.86	34.85	29.15	40.21
Others	0.45	(0.46)	1.43	1.67	3.63	5.24
Total	134.74	148.00	128.03	417.63	390.79	526.67
Less : Intersegment Revenue	-	-	-	-	-	-
Revenue from Operations	134.74	148.00	128.03	417.63	390.79	526.67
Segment Results before tax and finance cost						
Diagnostic Testing Services	19.93	27.40	17.18	72.05	65.29	79.43
Imaging Services	(1.85)	(0.50)	0.86	(2.30)	2.28	2.98
Others	0.03	(0.13)	(0.33)	(0.07)	(0.12)	(1.07)
Total	18.11	26.77	17.71	69.68	67.45	81.34
Add : Unallocable income net off other unallocable	1.67	1.13	1.52	2.80	3.04	6.07
Total Profit before exceptional items, share of loss of associate and income tax	19.78	27.91	19.23	72.47	70.49	87.41
Exceptional items	-	-	-	-	-	-
Share of profit/ (loss) of associate	0.13	0.36	0.49	0.60	0.86	1.18
Profit before tax	19.91	28.27	19.72	73.07	71.35	88.59
Segment assets						
Diagnostic Testing Services	388.35	353.64	307.12	388.35	307.12	297.72
Imaging Services	81.41	81.20	42.40	81.41	42.40	59.50
Others	-	-	-	-	-	-
Unallocated	150.01	157.85	251.40	150.01	251.40	275.50
	619.77	592.69	600.92	619.77	600.92	632.72
Segment Liabilities						
Diagnostic Testing Services	91.08	83.24	80.14	91.08	80.14	79.32
Imaging Services	12.04	11.77	3.99	12.04	3.99	7.16
Others	-	-	-	-	-	-
Unallocated	10.04	10.04	2.48	10.04	2.48	11.02
	113.16	105.05	86.61	113.16	86.61	97.50

- The above standalone unaudited financial results of the Company were reviewed and recommended by the Audit Committee on 1 February 2024 and subsequently approved by the Board of Directors at its meeting held on 1 February 2024. The review report has been filed with stock exchange and is available on the Company's website.
- The above unaudited standalone financial results for the quarter and nine month ended 31 December 2023 have been subjected to limited review by statutory auditors of the Company. The auditors have expressed an unmodified opinion in the limited review report for the quarter and nine month ended 31 December 2023.
- These unaudited standalone financial results have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.
- During the quarter ended 31 December 2023, the company has granted 68,456 equity stock options to employees under the new scheme- Employees Stock Option Schemes 2023. During the quarter ended and nine month ended 31 December 2023, 4,097 equity stock options and 23,937 equity stock options granted to employees under employees stock option schemes but not vested on account of discontinuance of services of these employees, respectively, has been added back to the pool, which would be available for subsequent distribution subject to statutory rules and regulations, as applicable. The Company has also allotted 22,633 equity shares of Rs.10 each fully paid up on exercise of options by employees in accordance with Employee Stock Option scheme during the quarter ended 31 December 2023.
- In accordance with Ind AS 108 'Operating Segments', segment information has been given in the consolidated financial results of the Company.
- Previous periods/years' figures have been regrouped/ reclassified wherever required, to make them comparable with the figure for the current period.

By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882



Rahul Guha
Managing
Director

DIN - 09588432

Mumbai, 1 February 2024

